Hospital Acquired Infection Control Market by Product & Service [Sterilization (Equipment, Services), Disinfectants (Hand, Skin, Surface, Wipes, Sprays)], End User (Hospitals, Nursing Homes, Diagnostic Centers), COVID-19 Impact - Global Forecast to 2026
[304 Pages Report] The hospital acquired infection control market is projected to reach USD 31.3 billion by 2026 from USD 29.1 billion in 2021, at a CAGR of 1.5% during the forecast period. The growth of the hospital acquired infection control market can largely be attributed to factors such as the high incidence of hospital-acquired infections, the increasing number of surgical procedures, the growing geriatric population and the increasing incidence of chronic diseases, technological advancements in sterilization equipment, and the growing awareness of environmental & personal hygiene due to COVID-19. The increasing use of E-beam sterilization, reintroduction of ethylene oxide sterilization, and the growing healthcare industry and outsourcing of operation to emerging countries are expected to offer high-growth opportunities for market players during the forecast period.
Currently, with the surge in COVID-19 cases, there is an increasing focus on personal hygiene along with the increasing production of medical nonwovens and single-use products such as face masks and gloves. This is further expected to drive the growth of the hospital acquired infection control market in the coming years. On the other hand, concerns regarding the safety of reprocessed instruments are expected to limit market growth to some extent in the coming years. This, along with factors such as the high cost of endoscope reprocessing and limited reimbursement in developing countries and end-user noncompliance with sterilization standards, is expected to restrain the growth of this market.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID-19 Impact on global hospital acquired infection control market
Temporary hospitals are also being set up to deal with the growing number of cases. Hence, the spread of COVID-19 has spurred a surge in demand for HAI services due to the growing cases of HAIs in hospital settings.
Various measures are being taken by companies as well as government bodies to drive market growth. For instance, the FDA has recommended that Sterigenics should reopen its ethylene oxide-based sterilization plant in the US. The plant had been shut due to harmful emissions, which were believed to be carcinogenic. In March 2020, the company received permission to reopen the plant for 21 days to sterilize PPE for healthcare workers to use during the COVID-19 pandemic. Such developments are anticipated to drive the growth of this market.
Equipment sterilization plays a critical role in preventing the spread of COVID-19 in healthcare settings. During the outbreak, patient-to-patient pathogen transmission via medical devices can be entirely prevented by properly sterilizing medical devices. The usage of reprocessed equipment to disinfect or sterilize medical devices is higher than normal during the pandemic since improper decontamination of surgical instruments, endoscopic devices, respiratory care devices, and reusable hemodialysis machines can increase the chances of COVID-19. This has increased the demand for sterilization services to ensure the proper sterilization of medical devices. Considering the higher demand for sterilization, governments and corporations are taking various initiatives to increase their sterilization capacity. Moreover, the COVID-19 pandemic has brought about a drastic shift in the consumption pattern of liquid disinfectants. The spread of the pandemic has made the concept of sanitizing and disinfecting even more prominent. The increasing need for improved hygiene in specialty clinics, hospitals, and ambulatory surgery centers to prevent the spread of the COVID-19 infection among patients and staff has driven the demand for liquid disinfectants.
Furthermore, the COVID-19 pandemic has affected the hospital sector more than any other end user segment. According to a survey conducted by the US Department of Health and Human Services (between March 23 and March 27, 2020), hospitals in the US reported a shortage of specialized providers needed to meet the anticipated patient surge. It also raised concerns that staff exposure to the virus may exacerbate staffing shortages and work overload. Factors such as the increasing demand for hospital beds and ICUs in countries with an increasing incidence of COVID-19 and an increasing number of temporary hospitals are driving the demand for disinfectant and sterilization products and services. Infrastructural expansion is evident globally as governments work to combat the virus and care for an increasing number of patients.
In London, a 4,000-bed temporary hospital was opened in a conference center in just nine days. This hospital was functional from April 3, 2020.
The Iranian military set up a 2,000-bed hospital in an exhibition center in just 48 hours. This facility includes three units and several isolation wards.
The increasing number of temporary hospitals, the growing need for remote care, and the rising influx of COVID-19 patients have resulted in the expansion of healthcare infrastructure and driven the demand for efficient hospital acquired infection control products and services.
Market Evolution After COVID-19
In 2020, the world was hit by the worst infectious disease that it had seen in decades. The infection of coronavirus hit the world at a level that was not imagined or expected, and the spread was also partially driven by hospital acquired infections as there were inadequate measures in place. Many medical professionals were also affected by COVID-19 and most of those cases were due to contact and infections spread via hospital environments.
The rate of HAIs significantly increased during the pandemic, with the rise in nursing hours. During the period, the medical device-related infections, catheter-associated urinary tract infections (CAUTIs), and central line-associated bloodstream infections (CLABSIs) were also increased, due to the change in the complexity of hospitalized patients and safety practices that were implemented to decrease virus transmission risk to healthcare providers. Thus, the control measures were taken at a very higher pace, which impacted the hospital-acquired infection control market positively during the pandemic time.
When the severity of the pandemic was realized, focus on hospital acquired infections was substantially increased and many measures were put in place to curb them. This created massive demand in the hospital acquired infection control equipment. However, in the current scenario, the demand for hospital acquired infection control devices is expected to see a drop as the pandemic has subsided, but increasing focus on hospital acquired infections is expected to keep the market afloat at a modest rate over the coming years.
Hospital Acquired Infection Control Market Dynamics
Driver: Increasing number of surgical procedures
Over the years, there has been a significant rise in the number of surgical procedures performed worldwide. According to the WHO (2019), approximately 235 million major surgical procedures are performed worldwide every year. This is attributed to the growing prevalence of obesity and other lifestyle diseases, the rising geriatric population, and the increasing incidence of spinal injuries and sports-related injuries. The growing number of surgical procedures performed has resulted in the increasing demand for different surgical equipment and medical devices. This is expected to drive the demand for hospital acquired infection services due to the proven benefits of sterilized products and growing awareness about their effectiveness in healthcare settings.
Restraint: Concerns regarding the safety of reprocessed instruments
Healthcare providers reprocess reusable medical devices to save money and reduce waste. Examples of reusable medical devices include surgical forceps, endoscopes, and stethoscopes. However, there are concerns about the safety and performance of reprocessed devices. Inadequate cleaning and sterilization of instruments can result in the retention of blood, tissue, and other biological debris in reusable devices, which increases the risk of surgical-site infections (SSIs) in patients. The debris can allow microbes to survive the subsequent disinfection or sterilization process, which could then lead to HAIs. Inadequate reprocessing can also result in other adverse patient outcomes, such as tissue irritation from residual reprocessing materials such as chemical disinfectants. These factors are limiting the acceptance of reprocessing among hospital administrators and physicians.
Opportunity : Reintroduction of ethylene oxide sterilization
Ethylene oxide is one of the most effective gaseous sterilizing agents for instruments susceptible to high temperatures, such as plastic instruments and instruments with electrical components. However, the CDC has stated that chronic exposure to ethylene oxide in workplaces can cause cancer. Also, ethylene oxide sterilization can irritate the skin and mucous membranes, resulting in CNS abnormalities in humans. Similarly, acute exposure to EtO gas may result in respiratory irritation, lung injury, headache, nausea, vomiting, diarrhea, shortness of breath, and cyanosis. EtO also degrades in the atmosphere by reacting with photochemically produced hydroxyl radicals. Authorities in several countries have defined regulatory frameworks to govern EtO usage in specific sterilization applications. In December 2016, the US Environmental Protection Agency (EPA), under the Integrated Risk Information System (IRIS) Assessment Program, declared ethylene oxide a probable human carcinogen. The European Union has already banned the use of ethylene oxide for any food fumigation due to safety and environmental concerns. The use of EtO for sterilizing ground spices is forbidden in the US.
However, with the growing number of COVID-19 cases worldwide, the adoption of EtO has increased to sterilize protective gear and single-use instruments before their initial use. This sterilization technology plays a vital role in enabling the sterilization of critical medical products and devices before reaching patients. According to the FDA, more than 20 billion devices sold in the US every year are sterilized with EtO, accounting for approximately 50% of the devices that require sterilization.
Challenge: Complications associated with hospital acquired infection control procedures
There are certain concerns related to the cleaning, disinfection, and sterilization of advanced medical devices. Inadequate sterilization and disinfection of these devices might expose patients to the risk of acquiring HAIs. Moreover, with the introduction of technologically advanced instruments such as endoscopes and analyzers in the market, there is a growing need for advanced sterilizers compatible with the automated endoscope reprocessors used for cleaning and disinfecting flexible endoscopes after each procedure. Inappropriate disinfection of these complex and delicate instruments can increase the risk of infection among patients. An AER that is difficult to use or one that breaks down frequently can significantly increase the risk of improper or ineffective endoscope cleaning and create costly delays. Currently, reprocessing of these instruments after every use is a major challenge faced by healthcare providers in complying with infection control standards.
The Association for the Advancement of Medical Instrumentation has several working groups focusing on developing standards in several areas aimed to address the challenges involved in reprocessing medical devices. These working groups are focusing on instructions for reusable device reprocessing, steam sterilization hospital practices, reusable surgical textiles processing, endoscope reprocessing, human factors for device reprocessing, quality systems for device reprocessing, and cleaning of reusable medical devices. Reprocessing medical devices is a difficult and complex job. Currently, hospitals are demanding sterile processing staff to be certified as it is a skill-intensive process.
The ethylene oxide (EtO) sterilization segment is expected to account for the largest share of the hospital acquired infection control market in 2020
Based on method, the market has been classified into ethylene oxide (EtO) sterilization, gamma sterilization, electron beam (e-beam) radiation sterilization, steam sterilization, x-ray irradiation, and other sterilization methods. The ethylene oxide (EtO) sterilization segment accounted for the largest share of the hospital acquired infection control market in 2020. This segment’s large share can be attributed to its extensive usage in various applications, including medical device sterilization, food testing, pharmaceutical sterilization, and sterilization and disinfection in the life sciences industry.
In 2020, the protective barrier segment accounted for the largest share of the global hospital acquired infection control market
Based on the products and services used in the control of HAIs, the hospital acquired infection control market is segmented into sterilization, disinfectors, endoscope reprocessing products, disinfectants, protective barriers, and other infection control products. In 2020, the protective barrier segment accounted for the largest share of the global hospital acquired infection control market. Once the pandemic situation returns to normalcy, the purchase of protective barriers will witness a downward trend. This is expected to result in a negative growth rate of the protective barriers segment.
The ambulatory surgical and diagnostic centers segment is expected to witness the highest CAGR during the forecast time
Based on end user, the hospital acquired infection control market has been segmented into hospitals & intensive care units (ICUs), ambulatory surgical and diagnostic centers, nursing homes and maternity centers, and other end users (dental clinics, trauma centers, and clinical laboratories). The ambulatory surgical and diagnostic centers segment is expected to witness the highest CAGR during the forecast time. The highest CAGR of this market is majorly attributed to the rising prevalence of HAIs, increasing adoption of single-use medical devices, growing medical devices industry, and rising number of surgical procedures worldwide. Also, increasing demand for minimally invasive surgeries, and growth in the development of outpatient services fuel the growth of the ambulatory surgical centers. In addition, the number of outpatients has increased significantly as a result of increased public health awareness and initiatives by the government to provide ambulatory healthcare services.
North America is expected to account for the largest share of the hospital acquired infection control market in 2020
In 2020, North America accounted for the largest share of the global hospital acquired infection market. Market growth in this region is characterized by the growing demand for and adoption of sterilization and disinfection products along with services as a result of the rising focus on healthy lifestyles and disease prevention among consumers. The surge in the geriatric population in the coming years and the subsequent increase in the prevalence of chronic diseases, the need for hospital acquired infection control to minimize the prevalence of HAIs, and implementation of favorable government initiatives and stringent regulations on sterilization and disinfection are also propelling the hospital acquired infection market in the region.
Key Market Players
The prominent players in this market are STERIS plc (US), Sotera Health Company (US), Getinge AB (Sweden), Advanced Sterilization Products (ASP) (US), Ecolab Inc. (US), 3M Company (US), MATACHANA GROUP (Spain), MMM Group (Germany), Belimed AG (Switzerland), Reckitt Benckiser (UK), Metrex Research LLC (UK), Miele Group (Germany), Pal International (UK), MELAG Medizintechnik GmbH & Co. KG (Germany), Contec, Inc. (US), MEDALKAN (Greece), Systec GmbH (Germany), C.B.M. S.r.l. Medical Equipment (Italy), Continental Equipment Company (US), and BGS Beta-Gamma-Service GmbH & Co. KG (Germany)
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Report Metric |
Details |
Market size available for years |
2019–2026 |
Base year considered |
2020 |
Forecast period |
2021–2026 |
Forecast units |
Value (USD Billion) |
Segments covered |
Products and services, end user |
Geographies covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa |
Companies covered |
STERIS plc (US), Sotera Health Company (US), Getinge AB (Sweden), Advanced Sterilization Products (ASP) (US), Ecolab Inc. (US), 3M Company (US), MATACHANA GROUP (Spain), MMM Group (Germany), Belimed AG (Switzerland), Reckitt Benckiser (UK), Metrex Research LLC (UK), Miele Group (Germany), Pal International (UK), MELAG Medizintechnik GmbH & Co. KG (Germany), Contec, Inc. (US), MEDALKAN (Greece), Systec GmbH (Germany), C.B.M. S.r.l. Medical Equipment (Italy), Continental Equipment Company (US), and BGS Beta-Gamma-Service GmbH & Co. KG (Germany) |
The study categorizes the global market based on products and services, end user, and regional and global level.
Global hospital acquired infection control market, by Product & Services
- Protective Barrier
- Sterilization
- Disinfectants
- Disinfectant, By Product
- Hand Disinfectants
- Surface Disinfectants
- Skin Disinfectants
- Instrument Disinfectants
- Disinfectant, By Formulation
- Liquid Disinfectants
- Disinfectant Wipes
- Disinfectant Sprays
- Disinfectant, By Product
- Disinfectors
- Endoscope Reprocessing Products
- Other Infection Control Products
Global hospital acquired infection control market, by End User
- Hospitals & ICUs
- Ambulatory Surgical & Diagnostic Centers
- Nursing Homes & Maternity Centers
Global hospital acquired infection control market, by Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of APAC
- Latin America
- Middle East & Africa
Recent Developments
- In 2021, STERIS acquired Cantel, a global provider of infection prevention products and services, through a US subsidiary, to diversify its vast portfolio of sterilization services.
- In 2021, Sterigenics S.A.S., a subsidiary of Sotera Health Company, expanded its ethylene oxide (EO) facility located in Rantigny, France, thereby increasing its European sterilization capacity.
- In 2020, Getinge launched the Getinge Solsus 66 steam sterilizer for hospitals and surgical instruments with increased capacity and operational reliability compared to other sterilizers
- In 2020, Sotera Health Company acquired Iotron, a key outsourced provider of E-beam sterilization services in North America. This acquisition helped expand its electron beam (E-beam) footprint and added new expertise to its Sterigenics business.
- In 2020, STERIS completed the acquisition of Key Surgical, a global provider of sterile processing, operating room, and endoscopy products. This acquisition enhanced the company’s product offering and STERIS’ revenue by 35%.
- In 2020, 3M partnered with Cummins to increase the production of high-efficiency particulate filters for use in 3M’s powered air-purifying respirators (PAPRs) due to the surge in demand for personal protective equipment due to the COVID-19 outbreak
Frequently Asked Questions (FAQ):
Which are the top industry players in the global hospital acquired infection control market?
The top market players in the global hospital acquired infection control market include STERIS plc (US), Sotera Health Company (US), Getinge AB (Sweden), Advanced Sterilization Products (ASP) (US), Ecolab Inc. (US), 3M Company (US), MATACHANA GROUP (Spain), MMM Group (Germany), Belimed AG (Switzerland), Reckitt Benckiser (UK), Metrex Research LLC (UK), Miele Group (Germany), Pal International (UK), MELAG Medizintechnik GmbH & Co. KG (Germany), Contec, Inc. (US), MEDALKAN (Greece), Systec GmbH (Germany), C.B.M. S.r.l. Medical Equipment (Italy), Continental Equipment Company (US), and BGS Beta-Gamma-Service GmbH & Co. KG (Germany).
Which global hospital acquired infection control products and services have been included in this report?
This report contains the following products and services segments:
- Protective Barrier
- Sterilization
- Disinfectants
- Disinfectant, By Product
- Hand Disinfectants
- Surface Disinfectants
- Skin Disinfectants
- Instrument Disinfectants
- Disinfectant, By Formulation
- Liquid Disinfectants
- Disinfectant Wipes
- Disinfectant Sprays
- Disinfectant, By Product
- Disinfectors
- Endoscope Reprocessing Products
- Other Infection Control Products
Which geographical region is dominating in the global hospital acquired infection control market?
In 2020, North America accounted for the largest share of the global hospital acquired infection market. Market growth in this region is characterized by the growing demand for and adoption of sterilization and disinfection products along with services as a result of the rising focus on healthy lifestyles and disease prevention among consumers. The surge in the geriatric population in the coming years and the subsequent increase in the prevalence of chronic diseases, the need for hospital acquired infection control to minimize the prevalence of HAIs, and implementation of favorable government initiatives and stringent regulations on sterilization and disinfection are also propelling the hospital acquired infection market in the region.
Which is the leading global hospital acquired infection control market, by products and services?
Based on the products and services used in the control of HAIs, the hospital acquired infection control market is segmented into sterilization, disinfectors, endoscope reprocessing products, disinfectants, protective barriers, and other infection control products. In 2020, the protective barrier segment accounted for the largest share of the global hospital acquired infection control market. Once the pandemic situation returns to normalcy, the purchase of protective barriers will witness a downward trend. This is expected to result in a negative growth rate of the protective barriers segment. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 31)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION & SCOPE
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.2.2 MARKET SEGMENTATION
FIGURE 1 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
1.4 STAKEHOLDERS
2 RESEARCH METHODOLOGY (Page No. - 35)
2.1 RESEARCH APPROACH
2.2 RESEARCH METHODOLOGY DESIGN
FIGURE 2 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET: RESEARCH DESIGN
2.2.1 SECONDARY RESEARCH
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.2.2.1 Key data from primary sources
2.2.2.2 Insights from primary experts
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION
FIGURE 8 TOP-DOWN APPROACH
FIGURE 9 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE HOSPITAL ACQUIRED INFECTION CONTROL MARKET (2021–2026)
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ESTIMATION
2.6 ASSUMPTIONS FOR THE STUDY
2.7 LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.8 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET
3 EXECUTIVE SUMMARY (Page No. - 49)
FIGURE 12 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 13 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANTS, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 14 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANTS, BY FORMULATION, 2021 VS. 2026 (USD MILLION)
FIGURE 15 HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 16 GEOGRAPHIC ANALYSIS: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET
4 PREMIUM INSIGHTS (Page No. - 55)
4.1 HOSPITAL ACQUIRED INFECTION CONTROL MARKET OVERVIEW
FIGURE 17 GROWING INCIDENCE OF HAIS AND INCREASING NUMBER OF SURGICAL PROCEDURES TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: MARKET, BY END USER AND COUNTRY
FIGURE 18 HOSPITALS & ICUS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC HOSPITAL-ACQUIRED INFECTION CONTROL MARKET IN 2020
4.3 HOSPITAL ACQUIRED INFECTION CONTROL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 CHINA TO REGISTER THE HIGHEST REVENUE GROWTH DURING THE FORECAST PERIOD
4.4 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY REGION (2019–2026)
FIGURE 20 NORTH AMERICA WILL CONTINUE TO DOMINATE THE HOSPITAL-ACQUIRED INFECTION CONTROL MARKET DURING THE FORECAST PERIOD
4.5 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 21 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 60)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
TABLE 3 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET: IMPACT ANALYSIS
5.2.1 MARKET DRIVERS
5.2.1.1 High incidence of hospital-acquired infections (HAIs)
5.2.1.2 Increasing number of surgical procedures
TABLE 4 US: PERCENTAGE INCREASE IN THE NUMBER OF SURGERIES PERFORMED
5.2.1.3 Growing geriatric population and the increasing incidence of chronic diseases
5.2.1.4 Technological advancements in sterilization equipment
5.2.1.5 Growing awareness of environmental & personal hygiene due to COVID-19
5.2.2 MARKET RESTRAINTS
5.2.2.1 Concerns regarding the safety of reprocessed instruments
5.2.2.2 Adverse effects of chemical disinfectants
5.2.2.3 High cost of endoscopy reprocessing and limited reimbursement in developing countries
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Reintroduction of ethylene oxide sterilization as a disinfectant in healthcare settings
5.2.3.2 Rising adoption of single-use medical nonwovens and devices
5.2.3.3 Growing healthcare industry and outsourcing of operations to emerging countries
FIGURE 22 INDIA: HEALTHCARE SECTOR GROWTH TREND (USD BILLION)
FIGURE 23 INDIA: NUMBER OF HOSPITALIZATIONS DUE TO VARIOUS DISEASES
5.2.4 MARKET CHALLENGES
5.2.4.1 Complications associated with hospital-acquired infection control procedures
5.2.4.2 End-user noncompliance with sterilization standards
TABLE 5 US: DECREASING COMPLIANCE AMONG END USERS
5.2.4.3 Development of alternative technologies for surface disinfection
6 INDUSTRY INSIGHTS (Page No. - 73)
6.1 INTRODUCTION
6.2 INDUSTRY TRENDS
6.2.1 INCREASING ADOPTION OF STERILIZATION USING NO2
6.2.2 ROBOTICS UTILIZATION FOR DISINFECTION
6.2.3 GROWING POPULARITY OF SINGLE-USE PRODUCTS
6.2.4 LAYERING/BUNDLING IN INFECTION PREVENTION
6.3 REGULATORY ANALYSIS
6.3.1 REGULATORY JURISDICTION
TABLE 6 FDA- AND EPA-REGISTERED PRODUCT CATEGORIES
6.3.2 BY REGION
6.3.2.1 North America
6.3.2.1.1 US
FIGURE 24 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR REPROCESSED MEDICAL DEVICES
6.3.2.1.2 Canada
TABLE 7 SPAULDING’S CLASSIFICATION OF MEDICAL EQUIPMENT/DEVICES AND REQUIRED LEVEL OF PROCESSING/REPROCESSING
6.3.2.2 Europe
TABLE 8 STERILIZATION STANDARDS IN THE EUROPEAN UNION
FIGURE 25 CE MARKING FOR REPROCESSED MEDICAL DEVICES
6.3.2.3 Asia Pacific
6.3.2.3.1 Japan
TABLE 9 SOME GUIDELINES FOLLOWED UNDER ISO IN JAPAN
TABLE 10 SPECIFICATIONS OF BIS RECOMMENDED FOR USE IN STERILIZATION PROCESSES
6.3.2.3.2 Australia
6.3.2.4 Latin America
6.3.3 ENFORCEMENT POLICY FOR STERILIZERS AND DISINFECTANT DEVICES DURING COVID-19
6.3.3.1 Sterilizers
TABLE 11 CLASSIFICATION REGULATIONS FOR STERILIZERS
6.3.3.2 Disinfectant devices
TABLE 12 CLASSIFICATION REGULATION FOR DISINFECTANT DEVICES
6.4 TECHNOLOGY ANALYSIS
6.4.1 KEY TECHNOLOGIES
6.4.2 COMPLEMENTARY TECHNOLOGIES
6.4.3 ADJACENT TECHNOLOGIES
6.5 PORTER’S FIVE FORCES ANALYSIS
TABLE 13 PORTER’S FIVE FORCES ANALYSIS (2020): HOSPITAL-ACQUIRED INFECTION CONTROL MARKET
6.5.1 THREAT FROM NEW ENTRANTS
6.5.2 THREAT FROM SUBSTITUTES
6.5.3 BARGAINING POWER OF SUPPLIERS
6.5.4 BARGAINING POWER OF BUYERS
6.5.5 INTENSITY OF COMPETITIVE RIVALRY
6.6 ECOSYSTEM ANALYSIS
FIGURE 26 INFECTION CONTROL MARKET: ECOSYSTEM ANALYSIS
6.7 VALUE CHAIN ANALYSIS
FIGURE 27 INFECTION CONTROL MARKET: VALUE CHAIN ANALYSIS
6.8 TRADE DATA
6.8.1 EXPORT DATA (USD)
6.8.2 IMPORT DATA (USD)
6.9 PATENT ANALYSIS
6.9.1 PATENT PUBLICATION TRENDS FOR HOSPITAL-ACQUIRED INFECTION CONTROL
FIGURE 28 PATENT PUBLICATION TRENDS (JANUARY 2011–JULY 2021)
6.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 29 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HOSPITAL-ACQUIRED INFECTION CONTROL PATENTS (JANUARY 2011–JULY 2021)
FIGURE 30 TOP APPLICANT COUNTRIES/REGIONS FOR HOSPITAL-ACQUIRED INFECTION CONTROL PATENTS (JANUARY 2011–JULY 2021)
TABLE 14 LIST OF FEW PATENTS IN THE HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, 2020–2021
6.10 IMPACT OF COVID-19 ON THE HOSPITAL-ACQUIRED INFECTION CONTROL MARKET
7 HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE (Page No. - 98)
7.1 INTRODUCTION
TABLE 15 COMMONLY USED INFECTION CONTROL CHEMICALS
TABLE 16 GLOBAL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
7.2 PROTECTIVE BARRIERS
7.2.1 RISING ADOPTION OF NONWOVENS IN SURGICAL INTERVENTIONS TO PROPEL MARKET GROWTH
TABLE 17 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR PROTECTIVE BARRIERS, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 STERILIZATION
TABLE 18 HOSPITAL ACQUIRED INFECTION CONTROL MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 19 GLOBAL MARKET FOR STERILIZATION, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.1 STERILIZATION EQUIPMENT
7.3.1.1 Effectiveness of sterilization equipment in sterilizing heat-sensitive products is expected to boost the market growth
TABLE 20 STERILIZATION EQUIPMENT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.2 STERILIZATION SERVICES
7.3.2.1 Increasing prevalence of HAIs and rising surgical interventions to drive market growth
TABLE 21 STERILIZATION SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.3 STERILIZATION CONSUMABLES & ACCESSORIES
7.3.3.1 Low cost and efficacy of sterilization consumables & accessories in monitoring the sterilization process to drive market growth
TABLE 22 STERILIZATION CONSUMABLES & ACCESSORIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 DISINFECTANTS
TABLE 23 JOINT COMMISSION STANDARDS FOR INFECTION CONTROL AND PREVENTION
TABLE 24 COMMON DISINFECTANTS USED IN HEALTHCARE SETTINGS
TABLE 25 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANTS, BY COUNTRY, 2019–2026 (USD MILLION)
7.4.1 DISINFECTANTS, BY TYPE
TABLE 26 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANTS, BY TYPE, 2019–2026 (USD MILLION)
7.4.1.1 Hand disinfectants
7.4.1.1.1 Increasing availability of various hand disinfection options to aid market growth
TABLE 27 HAND DISINFECTANTS OFFERED BY KEY MARKET PLAYERS
TABLE 28 HAND DISINFECTANTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.4.1.2 Surface disinfectants
7.4.1.2.1 Surface disinfectants limit the transfer of microorganisms that can occur through hand contact between contaminated surfaces and patients or staff
TABLE 29 SURFACE DISINFECTANTS OFFERED BY KEY MARKET PLAYERS
TABLE 30 SURFACE DISINFECTANTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.4.1.3 Skin disinfectants
7.4.1.3.1 Growing awareness about different HAIs and SSIs to aid market growth
TABLE 31 SKIN DISINFECTANTS OFFERED BY KEY MARKET PLAYERS
TABLE 32 SKIN DISINFECTANTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.4.1.4 Instrument disinfectants
7.4.1.4.1 Increasing number of surgeries and government initiatives for ensuring cleanliness in healthcare facilities are boosting the instrument disinfectants market
TABLE 33 SPAULDING’S CLASSIFICATION OF MEDICAL EQUIPMENT AND THE REQUIRED LEVEL OF REPROCESSING
TABLE 34 INSTRUMENT DISINFECTANTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.4.2 DISINFECTANTS, BY FORMULATION
TABLE 35 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANTS, BY FORMULATION, 2019–2026 (USD MILLION)
7.4.2.1 Liquid disinfectants
7.4.2.1.1 Liquid formulations are inexpensive and are an effective disinfection solution for porous and nonporous surfaces
TABLE 36 LIQUID DISINFECTANTS OFFERED BY KEY MARKET PLAYERS
TABLE 37 LIQUID DISINFECTANTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.4.2.2 Disinfectant wipes
7.4.2.2.1 Wipes help eliminate a broad spectrum of bacteria, viruses, and allergens
TABLE 38 DISINFECTANT WIPES OFFERED BY KEY MARKET PLAYERS
TABLE 39 DISINFECTANT WIPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.4.2.3 Disinfectant sprays
7.4.2.3.1 Disinfectant sprays are used in fogging techniques for antimicrobial control in hospital rooms and operation theaters
TABLE 40 DISINFECTANT SPRAYS OFFERED BY KEY MARKET PLAYERS
TABLE 41 DISINFECTANT SPRAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.5 DISINFECTORS
7.5.1 GROWING NEED TO REDUCE THE SPREAD OF HAIS IS DRIVING MARKET GROWTH
TABLE 42 HOSPITAL ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTORS, BY COUNTRY, 2019–2026 (USD MILLION)
7.6 ENDOSCOPE REPROCESSING PRODUCTS
7.6.1 INCREASING NUMBER OF ENDOSCOPY PROCEDURES CONDUCTED TO DRIVE MARKET GROWTH
TABLE 43 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR ENDOSCOPE REPROCESSING PRODUCTS, BY COUNTRY, 2019–2026 (USD MILLION)
7.7 OTHER INFECTION CONTROL PRODUCTS
TABLE 44 GLOBAL MARKET FOR OTHER INFECTION CONTROL PRODUCTS, BY COUNTRY, 2019–2026 (USD MILLION)
8 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY END USER (Page No. - 131)
8.1 INTRODUCTION
TABLE 45 HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
8.2 IMPACT OF COVID-19 ON THE END USERS IN THE HOSPITAL-ACQUIRED INFECTION CONTROL MARKET
8.3 HOSPITALS & INTENSIVE CARE UNITS (ICUS)
8.3.1 HIGH PREVALENCE OF HAIS TO DRIVE THE DEMAND FOR DISINFECTION AND STERILIZATION PRODUCTS AMONG HOSPITALS & INTENSIVE CARE UNITS
TABLE 46 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR HOSPITALS & INTENSIVE CARE UNITS, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 AMBULATORY SURGERY & DIAGNOSTIC CENTERS
8.4.1 GROWING NUMBER OF OUTPATIENTS AND AWARENESS OF MINIMALLY INVASIVE SURGERIES IS EXPECTED TO PROPEL MARKET GROWTH
TABLE 47 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR AMBULATORY SURGERY & DIAGNOSTIC CENTERS, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 NURSING HOMES & MATERNITY CENTERS
8.5.1 GROWING NEED TO ENSURE THE SAFETY OF ELDERLY PATIENTS AND RISING SURGICAL PROCEDURES IN WOMEN TO DRIVE THE ADOPTION OF HAI CONTROL PRODUCTS IN THIS END-USER SEGMENT
TABLE 48 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR NURSING HOMES & MATERNITY CENTERS, BY COUNTRY, 2019–2026 (USD MILLION)
8.6 OTHER END USERS
TABLE 49 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
9 HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY REGION (Page No. - 142)
9.1 INTRODUCTION
FIGURE 31 HOSPITAL ACQUIRED INFECTION CONTROL MARKET: GEOGRAPHIC SNAPSHOT (2020)
TABLE 50 GLOBAL MARKET, BY REGION, 2019–2026 (USD MILLION)
9.2 IMPACT OF COVID-19 ON THE HOSPITAL ACQUIRED INFECTION CONTROL MARKET
9.3 NORTH AMERICA
TABLE 51 NATIONAL ACUTE CARE HOSPITAL HAI METRICS
FIGURE 32 NORTH AMERICA: HOSPITAL ACQUIRED INFECTION CONTROL MARKET SNAPSHOT
TABLE 52 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 53 NORTH AMERICA: HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 54 NORTH AMERICA: MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 55 NORTH AMERICA: HOSPITAL ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 56 NORTH AMERICA: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 57 NORTH AMERICA: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 58 NORTH AMERICA: HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.1 US
9.3.1.1 Increasing prevalence of HAIs, high R&D expenditure, and the presence of well-established pharmaceutical, medical devices, and hospital industries to drive market growth
TABLE 59 US: HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 60 US: MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 61 US: HOSPITAL ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 62 US: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 63 US: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 64 US: HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.2 CANADA
9.3.2.1 High prevalence of HAIs to increase the adoption of infection control products in the country
TABLE 65 CANADA: HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 66 CANADA: MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 67 CANADA: HOSPITAL ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 68 CANADA: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 69 CANADA: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 70 CANADA: HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4 EUROPE
TABLE 71 EUROPE: HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 72 EUROPE: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 73 EUROPE: HOSPITAL ACQUIRED INFECTION CONTROL MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 74 EUROPE: MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 75 EUROPE: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 76 EUROPE: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 77 EUROPE: HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.1 GERMANY
9.4.1.1 Rising incidence of nosocomial infections and chronic diseases to drive growth in the market in Germany
TABLE 78 GERMANY: HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 79 GERMANY: MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 80 GERMANY: HOSPITAL ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 81 GERMANY: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 82 GERMANY: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 83 GERMANY: HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.2 FRANCE
9.4.2.1 High healthcare spending in the country to favor market growth
TABLE 84 FRANCE: HOSPITAL ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 85 FRANCE: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 86 FRANCE: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 FRANCE: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 88 FRANCE: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 89 FRANCE: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.3 UK
9.4.3.1 Rising number of surgical procedures to drive the market growth in the UK
TABLE 90 UK: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 91 UK: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 92 UK: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 93 UK: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 94 UK: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 95 UK: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.4 ITALY
9.4.4.1 Improving quality and accessibility to medical care and technologies to support market growth
TABLE 96 ITALY: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 97 ITALY: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 98 ITALY: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 99 ITALY: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 100 ITALY: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 101 ITALY: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.5 SPAIN
9.4.5.1 Rising incidence of chronic disorders to drive market growth
TABLE 102 SPAIN: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 103 SPAIN: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 104 SPAIN: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 105 SPAIN: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 106 SPAIN: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 107 SPAIN: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.6 REST OF EUROPE
TABLE 108 ROE: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 109 ROE: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 110 ROE: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 111 ROE: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 112 ROE: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 113 ROE: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5 ASIA PACIFIC
FIGURE 33 ASIA PACIFIC: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET SNAPSHOT
TABLE 114 ASIA PACIFIC: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 115 ASIA PACIFIC: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 116 ASIA PACIFIC: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 ASIA PACIFIC: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 118 ASIA PACIFIC: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 119 ASIA PACIFIC: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 120 ASIA PACIFIC: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5.1 JAPAN
9.5.1.1 Rising standard of care due to the increasing healthcare expenditure to support market growth
TABLE 121 JAPAN: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 122 JAPAN: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 123 JAPAN: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 124 JAPAN: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 125 JAPAN: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 126 JAPAN: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5.2 CHINA
9.5.2.1 China is the fastest-growing market for hospital-acquired infection control products and services
FIGURE 34 CHINA: TOTAL NUMBER OF HOSPITAL BEDS (2009–2019)
TABLE 127 CHINA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 128 CHINA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 129 CHINA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 130 CHINA: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 131 CHINA: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 132 CHINA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5.3 INDIA
9.5.3.1 Large patient population to support the growth of the hospital-acquired infection control market in the country
TABLE 133 INDIA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 134 INDIA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 135 INDIA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 136 INDIA: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 137 INDIA: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 138 INDIA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5.4 REST OF ASIA PACIFIC
FIGURE 35 NUMBER OF INBOUND VISITORS TO SOUTH KOREA FROM 2000 TO 2020 (IN MILLIONS)
TABLE 139 ROAPAC: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 140 ROAPAC: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 141 ROAPAC: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 142 ROAPAC: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 143 ROAPAC: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 144 ROAPAC: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.6 LATIN AMERICA
9.6.1 RISING NUMBER OF COSMETIC SURGERIES IN THE REGION TO DRIVE THE ADOPTION OF INFECTION CONTROL PRODUCTS
TABLE 145 LATIN AMERICA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 146 LATIN AMERICA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 147 LATIN AMERICA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 148 LATIN AMERICA: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 149 LATIN AMERICA: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 150 LATIN AMERICA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.7 MIDDLE EAST & AFRICA
9.7.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND FOCUS ON SAFETY MEASURES TO DRIVE MARKET GROWTH
TABLE 151 MIDDLE EAST & AFRICA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 152 MIDDLE EAST & AFRICA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR STERILIZATION, BY TYPE, 2019–2026 (USD MILLION)
TABLE 153 MIDDLE EAST & AFRICA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET FOR DISINFECTANT PRODUCTS, BY TYPE, 2019–2026 (USD MILLION)
TABLE 154 MIDDLE EAST & AFRICA: DISINFECTANTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 155 MIDDLE EAST & AFRICA: DISINFECTANTS MARKET, BY FORMULATION, 2019–2026 (USD MILLION)
TABLE 156 MIDDLE EAST & AFRICA: HOSPITAL-ACQUIRED INFECTION CONTROL MARKET, BY END USER, 2019–2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 201)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN THE HOSPITAL-ACQUIRED INFECTION CONTROL MARKET
10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN THE HOSPITAL-ACQUIRED INFECTION CONTROL MARKET
10.4 MARKET SHARE ANALYSIS
FIGURE 37 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET SHARE, BY KEY PLAYER, 2020
TABLE 157 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET: DEGREE OF COMPETITION
10.5 COMPETITIVE BENCHMARKING
10.5.1 COMPANY PRODUCT/SERVICE FOOTPRINT
TABLE 158 COMPANY PRODUCT OFFERING FOOTPRINT (20 COMPANIES)
TABLE 159 COMPANY END-USER FOOTPRINT (20 COMPANIES)
TABLE 160 COMPANY REGION FOOTPRINT (20 COMPANIES)
10.6 COMPETITIVE LEADERSHIP MAPPING
10.6.1 STARS
10.6.2 EMERGING LEADERS
10.6.3 PERVASIVE PLAYERS
10.6.4 PARTICIPANTS
FIGURE 38 HOSPITAL-ACQUIRED INFECTION CONTROL MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
10.7 COMPETITIVE SCENARIO
10.7.1 PRODUCT LAUNCHES & APPROVALS
TABLE 161 PRODUCT LAUNCHES & APPROVALS, 2018–2021
10.7.2 DEALS
TABLE 162 DEALS, 2018–2021
10.7.3 OTHER DEVELOPMENTS
TABLE 163 OTHER DEVELOPMENTS, 2018–2021
11 COMPANY PROFILES (Page No. - 215)
11.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1.1 STERIS PLC
TABLE 164 STERIS PLC: BUSINESS OVERVIEW
FIGURE 39 STERIS PLC: COMPANY SNAPSHOT (2021)
11.1.2 SOTERA HEALTH COMPANY
TABLE 165 SOTERA HEALTH COMPANY: BUSINESS OVERVIEW
FIGURE 40 SOTERA HEALTH COMPANY: COMPANY SNAPSHOT (2020)
11.1.3 GETINGE AB
TABLE 166 GETINGE AB: BUSINESS OVERVIEW
FIGURE 41 GETINGE AB: COMPANY SNAPSHOT (2020)
11.1.4 ADVANCED STERILIZATION PRODUCTS (ASP)
TABLE 167 ADVANCED STERILIZATION PRODUCTS: BUSINESS OVERVIEW
FIGURE 42 FORTIVE CORPORATION: COMPANY SNAPSHOT (2020)
11.1.5 ECOLAB INC.
TABLE 168 ECOLAB INC.: BUSINESS OVERVIEW
FIGURE 43 ECOLAB INC.: COMPANY SNAPSHOT (2020)
11.1.6 3M COMPANY
TABLE 169 3M COMPANY: BUSINESS OVERVIEW
FIGURE 44 3M COMPANY: COMPANY SNAPSHOT (2020)
11.1.7 MATACHANA GROUP
TABLE 170 MATACHANA GROUP: BUSINESS OVERVIEW
11.1.8 MMM GROUP
TABLE 171 MMM GROUP: BUSINESS OVERVIEW
11.1.9 BELIMED AG (A SUBSIDIARY OF METALL ZUG GROUP)
TABLE 172 BELIMED AG: BUSINESS OVERVIEW
FIGURE 45 METALL ZUG GROUP: COMPANY SNAPSHOT (2020)
11.1.10 RECKITT BENCKISER
TABLE 173 RECKITT BENCKISER: BUSINESS OVERVIEW
FIGURE 46 RECKITT BENCKISER: COMPANY SNAPSHOT (2020)
11.1.11 METREX RESEARCH LLC (A SUBSIDIARY OF DANAHER CORPORATION)
TABLE 174 METREX RESEARCH: BUSINESS OVERVIEW
FIGURE 47 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
11.1.12 MIELE GROUP
TABLE 175 MIELE GROUP: BUSINESS OVERVIEW
FIGURE 48 MIELE GROUP: COMPANY SNAPSHOT (2020)
11.1.13 PAL INTERNATIONAL
TABLE 176 PAL INTERNATIONAL: BUSINESS OVERVIEW
11.1.14 MELAG MEDIZINTECHNIK GMBH & CO. KG
TABLE 177 MELAG MEDIZINTECHNIK GMBH & CO. KG: BUSINESS OVERVIEW
11.1.15 CONTEC, INC.
TABLE 178 CONTEC, INC.: BUSINESS OVERVIEW
11.1.16 MEDALKAN
TABLE 179 MEDALKAN: BUSINESS OVERVIEW
11.1.17 SYSTEC GMBH
TABLE 180 SYSTEC GMBH: BUSINESS OVERVIEW
11.1.18 C.B.M. S.R.L. MEDICAL EQUIPMENT
TABLE 181 C.B.M. S.R.L. MEDICAL EQUIPMENT: BUSINESS OVERVIEW
11.1.19 CONTINENTAL EQUIPMENT COMPANY
TABLE 182 CONTINENTAL EQUIPMENT COMPANY: BUSINESS OVERVIEW
11.1.20 BETA-GAMMA-SERVICE GMBH & CO. KG
TABLE 183 BETA-GAMMA-SERVICE GMBH & CO. KG: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS
11.2.1 MIDWEST STERILIZATION CORPORATION
11.2.2 BLUE LINE STERILIZATION SERVICES LLC
11.2.3 STERIPACK GROUP
11.2.4 STERI-TEK
11.2.5 STERILIZATION SERVICES
12 APPENDIX (Page No. - 296)
12.1 INSIGHTS FROM INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.
Secondary Research
This research study involved the use of widespread secondary sources; directories; databases, such as D&B, Bloomberg Business, and Factiva; white papers; annual reports; and companies’ house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the hospital acquired infection control market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, technology perspectives, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the hospital acquired infection control market. The primary sources from the demand side include key executives from hospitals, pharmaceutical and medical device companies, and research institutes.
A breakdown of the primary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the hospital acquired infection control market was arrived at after data triangulation from different approaches, as mentioned below. After each approach, the weighted average of the approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Objectives of the Study
- To define, describe, segment, and forecast the hospital acquired infection control market by products and services, end user, and region
- To provide detailed information about factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players in the market and comprehensively analyze their core competencies2 and market shares
- To track and analyze competitive developments, such as acquisitions, product launches, expansions, collaborations, agreements, partnerships, and R&D activities, of the leading market players
- To benchmark players within the hospital acquired infection control market using the Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Geographic Analysis
- Further breakdown of the Rest of Europe hospital acquired infection control market into Denmark, Norway, and others
- Further breakdown of the Rest of Asia Pacific hospital acquired infection control market into Australia, New Zealand, and others
Growth opportunities and latent adjacency in Hospital Acquired Infection Control Market
Which is the top end-user that will reshape the Hospital Acquired Infection Control Market?
In what way recent developments impacting the Hospital Acquired Infection Control Market?
Which region contributing more to revenue growth in Hospital Acquired Infection Control Market?